blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2908853

EP2908853 - THY1 (CD90) AS A THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION [Right-click to bookmark this link]
Former [2015/35]THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION
[2018/19]
StatusNo opposition filed within time limit
Status updated on  11.10.2019
Database last updated on 09.09.2024
FormerThe patent has been granted
Status updated on  02.11.2018
FormerGrant of patent is intended
Status updated on  10.05.2018
FormerExamination is in progress
Status updated on  03.02.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
University of Rochester
601 Elmwood Avenue
Box OTT
Rochester, NY 14642 / US
[2015/35]
Inventor(s)01 / PHIPPS, Richard, P.
26 Greylock Ridge
Pittsford, NY 14534 / US
02 / WOELLER, Collynn, F.
920 Blackcherry Lane
Webster, NY 14580 / US
03 / FELDON, Steven, E.
39 Sandringham Road
Rocherster, NY 14610 / US
 [2015/35]
Representative(s)Adamson Jones
Park View House
58 The Ropewalk
Nottingham NG1 5DW / GB
[N/P]
Former [2015/35]Adamson Jones
BioCity Nottingham
Pennyfoot Street
Nottingham NG1 1GF / GB
Application number, filing date13847469.721.10.2013
[2015/35]
WO2013US65952
Priority number, dateUS201261716558P21.10.2012         Original published format: US 201261716558 P
[2015/35]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014063155
Date:24.04.2014
Language:EN
[2014/17]
Type: A1 Application with search report 
No.:EP2908853
Date:26.08.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 24.04.2014 takes the place of the publication of the European patent application.
[2015/35]
Type: B1 Patent specification 
No.:EP2908853
Date:05.12.2018
Language:EN
[2018/49]
Search report(s)International search report - published on:US24.04.2014
(Supplementary) European search report - dispatched on:EP15.04.2016
ClassificationIPC:A61K38/17, C07K14/705
[2016/20]
CPC:
C12N15/1138 (EP,US); A61K38/177 (US); A61K38/1774 (EP,US);
A61K9/0014 (US); A61K9/0048 (US); C07K14/70503 (EP,US);
C12N2310/113 (EP,US); C12N2310/141 (EP,US) (-)
Former IPC [2015/35]A61K39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/35]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:THY1 (CD90) ALS THERAPIE ZUR STEUERUNG VON FETTGEWEBEAKKUMULATION[2018/19]
English:THY1 (CD90) AS A THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION[2018/19]
French:THY1 (CD90) EN TANT QUE THÉRAPIE POUR RÉGULER L'ACCUMULATION DE TISSU ADIPEUX[2018/19]
Former [2015/35]THY1 (CD90) ALS NEUARTIGE THERAPIE ZUR STEUERUNG VON FETTGEWEBEAKKUMULATION
Former [2015/35]THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION
Former [2015/35]THY1 (CD90) EN TANT QUE NOUVELLE THÉRAPIE POUR RÉGULER L'ACCUMULATION DE TISSU ADIPEUX
Entry into regional phase08.05.2015National basic fee paid 
08.05.2015Search fee paid 
08.05.2015Designation fee(s) paid 
08.05.2015Examination fee paid 
Examination procedure08.05.2015Examination requested  [2015/35]
11.11.2016Amendment by applicant (claims and/or description)
01.02.2017Despatch of a communication from the examining division (Time limit: M06)
07.08.2017Reply to a communication from the examining division
16.11.2017Despatch of a communication from the examining division (Time limit: M04)
21.03.2018Reply to a communication from the examining division
11.05.2018Communication of intention to grant the patent
20.09.2018Fee for grant paid
20.09.2018Fee for publishing/printing paid
20.09.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.02.2017
Opposition(s)06.09.2019No opposition filed within time limit [2019/46]
Fees paidRenewal fee
27.10.2015Renewal fee patent year 03
27.10.2016Renewal fee patent year 04
27.10.2017Renewal fee patent year 05
29.10.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.10.2013
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MK05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
[2022/31]
Former [2021/34]HU21.10.2013
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
MT05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2021/33]HU21.10.2013
AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2021/26]AL05.12.2018
AT05.12.2018
CY05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2020/29]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
MC05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2020/17]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
TR05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/50]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SI05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/48]AL05.12.2018
AT05.12.2018
CZ05.12.2018
DK05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/39]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SK05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
IS05.04.2019
PT05.04.2019
Former [2019/37]AL05.12.2018
AT05.12.2018
CZ05.12.2018
EE05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RO05.12.2018
RS05.12.2018
SE05.12.2018
SM05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/35]AL05.12.2018
AT05.12.2018
CZ05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
PL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/34]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
IT05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/33]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
PT05.04.2019
Former [2019/30]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
NL05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/26]AL05.12.2018
AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/25]AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
RS05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/24]AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
SE05.12.2018
BG05.03.2019
NO05.03.2019
GR06.03.2019
Former [2019/23]AT05.12.2018
ES05.12.2018
FI05.12.2018
HR05.12.2018
LT05.12.2018
LV05.12.2018
BG05.03.2019
NO05.03.2019
Former [2019/22]FI05.12.2018
LT05.12.2018
BG05.03.2019
NO05.03.2019
Former [2019/21]FI05.12.2018
LT05.12.2018
NO05.03.2019
Former [2019/20]LT05.12.2018
NO05.03.2019
Documents cited:Search[X]WO9945951  (HARVARD COLLEGE [US], et al) [X] 10-15 * page 1, line 32 - page 5, line 24 * * page 13, line 23 - page 14, line 10 *;
 [XI]WO2010133970  (ETH ZUERICH [CH], et al) [X] 1,3,5,8,9,16,17 * the whole document * [I] 6,7;
 [X]WO2011119199  (EINSTEIN COLL MED [US], et al) [X] 1,3,8,9 * paragraphs [0014] , [0041] , [0042] , [0045] , [0046] , [0049] , [0050] , [0071] , [0072] *;
 [X]  - M. DEVASAHAYAM ET AL, "The glycan processing and site occupancy of recombinant Thy-1 is markedly affected by the presence of a glycosylphosphatidylinositol anchor", GLYCOBIOLOGY, US, (19991201), vol. 9, no. 12, doi:10.1093/glycob/9.12.1381, ISSN 0959-6658, pages 1381 - 1387, XP055263782 [X] 10-15 * abstract * * page 1383, column r * * page 1385, column r, paragraph l - page 1386, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1093/glycob/9.12.1381
 [A]  - BRIAN M. VARISCO ET AL, "Thy-1 Signals through PPAR[gamma] to Promote Lipofibroblast Differentiation in the Developing Lung", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY., NEW YORK, NY, US, (20120601), vol. 46, no. 6, doi:10.1165/rcmb.2011-0316OC, ISSN 1044-1549, pages 765 - 772, XP055263762 [A] 1,10 * abstract *

DOI:   http://dx.doi.org/10.1165/rcmb.2011-0316OC
International search[X]US2004266993  (EVANS GLEN A [US]);
 [Y]US2012015001  (PHIPPS RICHARD P [US], et al);
 [X]  - LEHMANN ET AL., "Novel anti-adipogenic activity produced by human fibroblasts.", AM J PHYSIOL CELL PHYSIOL., (201009), vol. 299, no. 3, pages C672 - C681, XP055251598

DOI:   http://dx.doi.org/10.1152/ajpcell.00451.2009
 [Y]  - TRAJKOVSKI ET AL., "MICRORNAS 103 AND 107 REGULATE INSULIN SENSITIVITY.", NATURE, (20110608), vol. 474, no. 7353, pages 649 - 653, XP055222703

DOI:   http://dx.doi.org/10.1038/nature10112
by applicantUS4237224
 US5059421
 US5138045
 WO9306223
 WO9307283
 WO9307282
 US5214136
 US5407926
 US5631237
 US5643599
 US5653996
 US5681811
 US5849586
 US5871727
 US5885613
 US5885808
 US5981225
 US5994132
 US6001557
 US6033908
 US6057155
 US6060463
 US6074673
 US6149935
 US6153737
 US6210717
 WO0130337
 US6235886
 WO0168053
 US6335434
 US6464687
 US6528631
 WO2004043480
 WO2004058289
 US2004147026
 US2004170962
 US6790657
 US6835718
 US2005101582
 WO2006015299
 WO2006044206
 EP1674068
 WO2006091297
 US2008118500
 WO2008151639
 US2009036552
 US2010286378
 WO2011117353
 US2011245481
 WO2012069059
 US2012245219
    - JUONALA et al., "Childhood Adiposity, Adult Adiposity, and Cardiovascular Risk Factors", N Engl J Med, (20110000), vol. 365, no. 20, pages 1876 - 85
    - LUDWIG, D.S., "Childhood Obesity--the Shape of Things to Come", N Engl J Med, (20070000), vol. 357, no. 23, pages 2325 - 7
    - TROSKO et al., "Factors to Consider in the Use of Stem Cells for Pharmaceutic Drug Development and for Chemical Safety Assessment", Toxicology, (20100000), vol. 270, no. 1, pages 18 - 34, XP026982363
    - JANESICK et al., "Endocrine Disrupting Chemicals and the Developmental Programming of Adipogenesis and Obesity", Birth Defects Res C Embryo Today, (20110000), vol. 93, no. 1, pages 34 - 50
    - GRUN et al., "Environmental Obesogens: Organotins and Endocrine Disruption Via Nuclear Receptor Signaling", Endocrinology, (20060000), vol. 147, no. 6, pages S50 - 5
    - JANESICK et al., "Obesogens, Stem Cells and the Developmental Programming of Obesity", Int JAndrol, (20120000), vol. 35, no. 3, pages 437 - 48
    - BOEKELHEIDE et al., "Predicting Later-Life Outcomes of Early-Life Exposures", Environ Health Perspect, (20120000), vol. 120, no. 10, pages 1353 - 61
    - BAHN, R.S., "Graves' Ophthalmopathy", N Engl J Med, (20100000), vol. 362, no. 8, pages 726 - 38
    - KURIYAN et al., "The Eye and Thyroid Disease", Curr Opin Ophthalmol, (20080000), vol. 19, no. 6, pages 499 - 506
    - LEHMANN et al., "Novel Anti-adipogenic Activity Produced by Human Fibroblasts", Am J Physiol Cell Physiol, (20100000), vol. 299, no. 3, doi:doi:10.1152/ajpcell.00451.2009, pages C672 - 81, XP055251598

DOI:   http://dx.doi.org/10.1152/ajpcell.00451.2009
    - TRAJKOVSKI et al., "MicroRNAs 103 and 107 Regulate Insulin Sensitivity", Nature, (20110000), vol. 474, no. 7353, doi:doi:10.1038/nature10112, pages 649 - 53, XP055222703

DOI:   http://dx.doi.org/10.1038/nature10112
    - SANDERS et al., "Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts", Am J Respir Cell Mol Biol, (20110000), vol. 45, no. 1, pages 16 - 23
    - PHIPPS et al., "Characterization of Two Major Populations of Lung Fibroblasts: Distinguishing Morphology and Discordant Display of Thy 1 and Class II MHC", Am JRespir Cell Mol Biol, (19890000), vol. 1, no. 1, pages 65 - 74
    - BAGLOLE et al., "More Than Structural Cells, Fibroblasts Create and Orchestrate the Tumor Microenvironment", Immunol Invest, (20060000), vol. 35, no. 3-4, pages 297 - 325
    - BRADLEY et al., "Roles and Regulation of Thyl, a Context-Dependent Modulator of Cell Phenotype", Biofactors, (20090000), vol. 35, no. 3, pages 258 - 65
    - PEI et al., "Thy-1 Distinguishes Human Corneal Fibroblasts and Myofibroblasts from Keratocytes", Exp Eye Res, (20040000), vol. 79, no. 5, doi:doi:10.1016/j.exer.2004.08.002, pages 705 - 12, XP004608949

DOI:   http://dx.doi.org/10.1016/j.exer.2004.08.002
    - KOUMAS et al., "Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes", Am J Pathol, (20030000), vol. 163, no. 4, pages 1291 - 300
    - KOUMAS et al., "Fibroblast Subsets in the Human Orbit: Thy-1+ and Thy-1-Subpopulations Exhibit Distinct Phenotypes", Eur J Immunol, (20020000), vol. 32, no. 2, pages 477 - 85
    - GUO et al., "Mast Cell-Derived Prostaglandin D2 Controls Hyaluronan Synthesis in Human Orbital Fibroblasts Via Dpi Activation: Implications for Thyroid Eye Disease", J Biol Chem, (20100000), vol. 285, no. 21, pages 15794 - 804
    - KOO et al., "Fyn Inhibition by Cycloalkane-Fused 1,2-Dithiole-3-thiones Enhances Antioxidant Capacity and Protects Mitochondria from Oxidative Injury", Mol Pharmacol, (20120000), vol. 82, pages 27 - 36
    - WANG et al., "Identification and Characterization of a Promoter Cassette Conferring Adipocyte-specific Gene Expression", Endocrinol, (20100000), vol. 151, no. 6, pages 2933 - 9
    - KURLAWALLA-MARTINEZ et al., "Insulin Hypersensitivity and Resistance to Streptozotocin-induced Diabetes in Mice Lacking PTEN in Adipose Tissue", Mol Cell Biol., (20050000), vol. 25, no. 6, pages 2498 - 2510
    - ROBERTS; LAUER, "Maximizing Gene Expression On a Plasmid Using Recombination In Vitro", Methods in Enzymology, (19790000), vol. 68, pages 473 - 82, XP001314595
    - Proc. Natl. Acad. Sci. USA, (19870000), vol. 84, page 7851
    - Biochemistry, (19890000), vol. 28, page 908
    - BANGHAM et al., J. Mol. Biol., (19650000), vol. 13, pages 238 - 252
    - BERKNER, Biotechniques, (19880000), vol. 6, pages 616 - 627
    - ROSENFELD et al., Science, (19910000), vol. 252, pages 431 - 434
    - CHATTERJEE et al., Science, (19920000), vol. 258, pages 1485 - 1488
    - WALSH et al., Proc. Nat'lAcad. Sci. USA, (19920000), vol. 89, pages 7257 - 7261
    - WALSH et al., J. Clin. Invest., (19940000), vol. 94, pages 1440 - 1448
    - FLOTTE et al., J. Biol. Chem., (19930000), vol. 268, pages 3781 - 3790
    - PONNAZHAGAN et al., J. Exp. Med., (19940000), vol. 179, pages 733 - 738
    - MILLER et al., Proc. Nat'l Acad. Sci. USA, (19940000), vol. 91, pages 10183 - 10187
    - EINERHAND et al., Gene Ther., (19950000), vol. 2, pages 336 - 343
    - LUO et al., Exp. Hematol., (19950000), vol. 23, pages 1261 - 1267
    - ZHOU et al., Gene Ther., (19960000), vol. 3, pages 223 - 229
    - FLOTTE et al., Proc. Nat'l Acad. Sci. USA, (19930000), vol. 90, pages 10613 - 10617
    - KAPLITT et al., Nature Genet., (19940000), vol. 8, pages 148 - 153
    - KIM et al., "ADD1/SREBP1 Activates PPARgamma Through the Production of Endogenous Ligand", Proc Natl Acad Sci USA, (19980000), vol. 95, no. 8, pages 4333 - 7
    - FORMAN et al., "15-Deoxy-delta 12, 14-prostaglandin J2 is a Ligand for the Adipocyte Determination Factor PPARgamma", Cell, (19950000), vol. 83, no. 5, doi:doi:10.1016/0092-8674(95)90193-0, pages 803 - 12, XP002935823

DOI:   http://dx.doi.org/10.1016/0092-8674(95)90193-0
    - CHEN et al., "Krox20 Stimulates Adipogenesis Via C/Ebpbeta-Dependent and -Independent Mechanisms", Cell Metab, (20050000), vol. 1, no. 2, pages 93 - 106
    - GRONTVED et al., "Medl4 Tethers Mediator to the N-Terminal Domain of Peroxisome Proliferator-Activated Receptor Gamma and Is Required for Full Transcriptional Activity and Adipogenesis", Mol Cell Biol, (20100000), vol. 30, no. 9, pages 2155 - 69
    - JUNG et al., "Peroxisome Proliferator-Activated Receptor Gamma/Signal Transducers and Activators of Transcription 5a Pathway Plays a Key Factor in Adipogenesis of Human Bone Marrow-Derived Stromal Cells and 3t3-Ll Preadipocytes", Stem Cells Dev, (20110000), vol. 21, no. 3, pages 465 - 75
    - PANTOJA et al., "Glucocorticoid Signaling Defines a Novel Commitment State During Adipogenesis in Vitro", Mol Biol Cell, (20080000), vol. 19, no. 10, pages 4032 - 41
    - ROSS et al., "Dual Roles for the Notch Target Gene Hes-1 in the Differentiation of 3t3-Ll Preadipocytes", Mol Cell Biol, (20040000), vol. 24, no. 8, doi:doi:10.1128/MCB.24.8.3505-3513.2004, pages 3505 - 13, XP055015041

DOI:   http://dx.doi.org/10.1128/MCB.24.8.3505-3513.2004
    - SARRUF et al., "Cyclin D3 Promotes Adipogenesis through Activation of Peroxisome Proliferator-Activated Receptor Gamma", Mol Cell Biol, (20050000), vol. 25, no. 22, pages 9985 - 95
    - XUE et al., "Distinct Stages in Adipogenesis Revealed by Retinoid Inhibition of Differentiation after Induction of PPARgamma", Mol Cell Biol, (19960000), vol. 16, no. 4, pages 1567 - 75, XP000577882
    - YING et al., "Impaired Adipogenesis Caused by a Mutated Thyroid Hormone Alphal Receptor", Mol Cell Biol, (20070000), vol. 27, no. 6, pages 2359 - 71
    - RIU et al., "Peroxisome Proliferator-Activated Receptor Gamma is a Target for Halogenated Analogs of Bisphenol A", Environ Health Perspect, (20110000), vol. 119, no. 9, pages 1227 - 32
    - KIRCHNER et al., "Prenatal Exposure to the Environmental Obesogen Tributyltin Predisposes Multipotent Stem Cells to Become Adipocytes", Mol Endocrinol, (20100000), vol. 24, no. 3, pages 526 - 39
    - GRUN et al., "Endocrine-Disrupting Organotin Compounds are Potent Inducers of Adipogenesis in Vertebrates", Mol Endocrinol, (20060000), vol. 20, no. 9, pages 2141 - 55
    - ANTIZAR-LADISLAO, B, "Environmental Levels, Toxicity and Human Exposure to Tributyltin (TBT)-Contaminated Marine Environment. A Review", Environ Int, (20080000), vol. 34, no. 2, doi:doi:10.1016/j.envint.2007.09.005, pages 292 - 308, XP029235019

DOI:   http://dx.doi.org/10.1016/j.envint.2007.09.005
    - BARTEL, D.P., "MicroRNAS: Target Recognition and Regulatory Functions", Cell, (20090000), vol. 136, no. 2, doi:doi:10.1016/j.cell.2009.01.002, pages 215 - 33, XP055011377

DOI:   http://dx.doi.org/10.1016/j.cell.2009.01.002
    - FURER et al., "The Role of MicroRNA in Rheumatoid Arthritis and Other Autoimmune Diseases", Clin Immunol, (20100000), vol. 136, no. 1, doi:doi:10.1016/j.clim.2010.02.005, pages 1 - 15, XP027074866

DOI:   http://dx.doi.org/10.1016/j.clim.2010.02.005
    - XIE et al., "MicroRNAS Induced During Adipogenesis That Accelerate Fat Cell Development Are Downregulated in Obesity", Diabetes, (20090000), vol. 58, no. 5, doi:doi:10.2337/db08-1299, pages 1050 - 7, XP002598120

DOI:   http://dx.doi.org/10.2337/db08-1299
    - CROW, J.M., "Obesity: Insensitive Issue", Nature, (20120000), vol. 486, pages 12 - 13
    - HASLER et al., "A Functional Methylome Map of Ulcerative Colitis", Genome Res, (20120000), vol. 22, no. 11, pages 2137 - 7
    - GUO et al., "Mammalian MicroRNAs Predominantly Act to Decrease Target mRNA Levels", Nature, (20100000), vol. 466, doi:doi:10.1038/nature09267, pages 835 - 840, XP055326492

DOI:   http://dx.doi.org/10.1038/nature09267
    - LEWIS et al., "Conserved Seed Pairing, Often Flanked by Adenosines, Indicates That Thousands of Human Genes are MicroRNA Targets", Cell, (20050000), vol. 120, pages 15 - 20
    - HAN; SMITH, "T Helper Type 1 and Type 2 Cytokines Exert Divergent Influence on the Induction of Prostaglandin E2 and Hyaluronan Synthesis by Interleukin-lbeta in Orbital Fibroblasts: Implications for the Pathogenesis of Thyroid-Associated Ophthalmopathy", Endocrinology, (20060000), vol. 147, no. 1, pages 13 - 9
    - REDFERN; MCDERMOTT, "Toll-Like Receptors in Ocular Surface Disease", Experimental Eye Research, (20100000), vol. 90, no. 6, pages 679 - 87, XP027051364
    - REDFERN et al., "Toll-Like Receptor Activation Modulates Antimicrobial Peptide Expression by Ocular Surface Cells", Experimental Eye Research, (20110000), vol. 92, no. 3, doi:doi:10.1016/j.exer.2010.12.005, pages 209 - 20, XP028186093

DOI:   http://dx.doi.org/10.1016/j.exer.2010.12.005
    - SMITH et al., "Unique Attributes of Orbital Fibroblasts and Global Alterations in Igf-1 Receptor Signaling Could Explain Thyroid-Associated Ophthalmopathy", Thyroid, (20080000), vol. 18, no. 9, pages 983 - 8
    - FELDON et al., "Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins That Drive Human Orbital Fibroblast Differentiation to Adipocytes", Am J Pathol, (20060000), vol. 169, no. 4, pages 1183 - 93
    - PHIPPS et al., "Characterization of Two Major Populations of Lung Fibroblasts: Distinguishing Morphology and Discordant Display of Thy 1 and Class Ii Mhc", Am JRespir Cell Mol Biol, (19890000), vol. 1, no. 1, pages 65 - 74
    - KAMINSKI et al., "Susceptibility of Ocular Tissues to Autoimmune Diseases", Ann N YAcad Sci, (20030000), vol. 998, pages 362 - 74
    - KUMAR; BAHN, "Relative Overexpression of Macrophage-Derived Cytokines in Orbital Adipose Tissue from Patients with Graves' Ophthalmopathy", J Clin Endocrinol Metab, (20030000), vol. 88, no. 9, pages 4246 - 50
    - LEHMANN et al., "Immune Mechanisms in Thyroid Eye Disease", Thyroid, (20080000), vol. 18, no. 9, pages 959 - 65
    - BUJALSKA et al., "Characterisation of llbeta-Hydroxysteroid Dehydrogenase 1 in Human Orbital Adipose Tissue: A Comparison with Subcutaneous and Omental Fat", J Endocrinol, (20070000), vol. 192, no. 2, pages 279 - 88
    - LUDGATE; BAKER, "Unlocking the Immunological Mechanisms of Orbital Inflammation in Thyroid Eye Disease", Clin Exp Immunol, (20020000), vol. 127, no. 2, pages 193 - 8
    - PRABHAKAR et al., "Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy", Endocr Rev, (20030000), vol. 24, no. 6, pages 802 - 35
    - KOUMAS et al., "Fibroblast Heterogeneity: Existence of Functionally Distinct Thy 1(+) and Thy l(-) Human Female Reproductive Tract Fibroblasts", Am J Pathol, (20010000), vol. 159, no. 3, pages 925 - 35, XP001064501
    - SMITH et al., "Orbital Fibroblast Heterogeneity May Determine the Clinical Presentation of Thyroid-Associated Ophthalmopathy", J Clin Endocrinol Metab, (20020000), vol. 87, no. 1, pages 385 - 92
    - HWANG et al., "Orbital Fibroblasts from Patients with Thyroid-Associated Ophthalmopathy Overexpress Cd40: Cd154 Hyperinduces 11-6, 11-8, and Mcp-1", Invest Ophthalmol Vis Sci, (20090000), vol. 50, no. 5, pages 2262 - 8
    - RAYCHAUDHURI et al., "Pge2 Induces 11-6 in Orbital Fibroblasts through Ep2 Receptors and Increased Gene Promoter Activity: Implications to Thyroid-Associated Ophthalmopathy", PLoS One, (20100000), vol. 5, no. 12, page e15296
    - KOUMAS et al., "Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes", Am JPathol, (20030000), vol. 163, no. 4, pages 1291 - 300
    - LEHMANN et al., "Novel Anti-Adipogenic Activity Produced by Human Fibroblasts", Am J Physiol Cell Physiol, (20100000), vol. 299, no. 3, doi:doi:10.1152/ajpcell.00451.2009, pages C672 - C681, XP055251598

DOI:   http://dx.doi.org/10.1152/ajpcell.00451.2009
    - BRADLEY et al., "Roles and Regulation of Thy-1, a Context-Dependent Modulator of Cell Phenotype", Biofactors, (20090000), vol. 35, no. 3, pages 258 - 65
    - KEMSHEAD et al., "Human Thy-1: Expression on the Cell Surface of Neuronal and Glial Cells", Brain Res, (19820000), vol. 236, no. 2, doi:doi:10.1016/0006-8993(82)90727-2, pages 451 - 61, XP024256495

DOI:   http://dx.doi.org/10.1016/0006-8993(82)90727-2
    - COHEN et al., "Thyl up-Regulates Fasl Expression in Lung Myofibroblasts Via Src Family Kinases", Am JRespir Cell Mol Biol, (20090000), vol. 40, no. 2, pages 231 - 8
    - PHIPPS et al., "Differential Expression of Interleukin 1 Alpha by Thy-1+ and Thy-1- Lung Fibroblast Subpopulations: Enhancement of Interleukin 1 Alpha Production by Tumor Necrosis Factor-Alpha", Eur J Immunol, (19900000), vol. 20, no. 8, pages 1723 - 7
    - SHAN et al., "Thy-1 Attenuates Tnf-Alpha-Activated Gene Expression in Mouse Embryonic Fibroblasts Via Src Family Kinase", PLoS One, (20100000), vol. 5, no. 7, page ell662
    - BRUN et al., "Differential Activation of Adipogenesis by Multiple PPAR Isoforms", Genes Dev, (19960000), vol. 10, no. 8, pages 974 - 84, XP000577792
    - KIM; SPIEGELMAN, "Addl/Srebpl Promotes Adipocyte Differentiation and Gene Expression Linked to Fatty Acid Metabolism", Genes Dev, (19960000), vol. 10, no. 9, pages 1096 - 107
    - SPIEGELMAN et al., "Regulation of Adipogenesis and Energy Balance by PPARgamma and PGC-1", Int J Obes Relat Metab Disord, (20000000), vol. 24, no. 4, pages S8 - 10
    - TONTONOZ et al., "Regulation of Adipocyte Gene Expression and Differentiation by Peroxisome Proliferator Activated Receptor Gamma", Curr Opin Genet Dev, (19950000), vol. 5, no. 5, pages 571 - 6
    - TONTONOZ; SPIEGELMAN, "Fat and Beyond: The Diverse Biology of PPARgamma", Annu Rev Biochem, (20080000), vol. 77, doi:doi:10.1146/annurev.biochem.77.061307.091829, pages 289 - 312, XP055493833

DOI:   http://dx.doi.org/10.1146/annurev.biochem.77.061307.091829
    - BARTEL, D.P., "Micrornas: Target Recognition and Regulatory Functions", Cell, (20090000), vol. 136, no. 2, doi:doi:10.1016/j.cell.2009.01.002, pages 215 - 33, XP055011377

DOI:   http://dx.doi.org/10.1016/j.cell.2009.01.002
    - CARTHEW SONTHEIMER, "Origins and Mechanisms of Mirnas and Sirnas", Cell, (20090000), vol. 136, no. 4, doi:doi:10.1016/j.cell.2009.01.035, pages 642 - 55, XP055091221

DOI:   http://dx.doi.org/10.1016/j.cell.2009.01.035
    - CHOI et al., "Anti-Diabetic Drugs Inhibit Obesity-Linked Phosphorylation of PPARgamma by Cdk5", Nature, (20100000), vol. 466, no. 7305, pages 451 - 6
    - AOUADI et al., "Inhibition of P38mapk Increases Adipogenesis from Embryonic to Adult Stages", Diabetes, (20060000), vol. 55, no. 2, pages 281 - 9
    - BURNS; VANDEN HEUVEL, "Modulation of PPAR Activity Via Phosphorylation", Biochim Biophys Acta, (20070000), vol. 1771, no. 8, doi:doi:10.1016/j.bbalip.2007.04.018, pages 952 - 60, XP022189880

DOI:   http://dx.doi.org/10.1016/j.bbalip.2007.04.018
    - ENGELMAN et al., "Specific Inhibitors of P38 Mitogen-Activated Protein Kinase Block 3T3-L1 Adipogenesis", JBiol Chem, (19980000), vol. 273, no. 48, doi:doi:10.1074/jbc.273.48.32111, pages 32111 - 20, XP008124632

DOI:   http://dx.doi.org/10.1074/jbc.273.48.32111
    - HU et al., "Inhibition of Adipogenesis Through Map Kinase-Mediated Phosphorylation of PPARgamma", Science, (19960000), vol. 274, no. 5295, doi:doi:10.1126/science.274.5295.2100, pages 2100 - 3, XP055000069

DOI:   http://dx.doi.org/10.1126/science.274.5295.2100
    - PRUSTY et al., "Activation of MEK/ERK Signaling Promotes Adipogenesis by Enhancing Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) and C/EBPalpha Gene Expression During the Differentiation of 3T3-L1 Preadipocytes", J Biol Chem, (20020000), vol. 277, no. 48, pages 46226 - 32
    - CHEN et al., "Meox2 Regulates Nuclear Factor-Kappab Activity in Vascular Endothelial Cells through Interactions with P65 and Ikappabbeta", Cardiovascular Research, (20100000), vol. 87, no. 4, pages 723 - 31
    - MANDEVILLE et al., "Impact of the Loss of Hoxa5 Function on Lung Alveogenesis", American Journal of Pathology, (20060000), vol. 169, no. 4, pages 1312 - 27
    - URBICH et al., "Role of Micrornas in Vascular Diseases, Inflammation, and Angiogenesis", Cardiovasc Res, (20080000), vol. 79, no. 4, doi:doi:10.1093/cvr/cvn156, pages 581 - 8, XP002559946

DOI:   http://dx.doi.org/10.1093/cvr/cvn156
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.